NFKB1 and pulmonary fibrosis: By deactivating NF-κB, GLP-1 receptor agonists greatly reduce bleomycin (BLM)-induced lung damage and fibrosis in mice (182).Exendin-4, meanwhile, reduced hyperglycemia-related lung damage by lowering oxidative stress and promoting cell growth (183).DPP-4 inhibitors and PPAR-γ agonists have proven useful in the treatment of pulmonary fibrosis.